A new trading day began on Monday, with Recursion Pharmaceuticals Inc (NASDAQ: RXRX) stock price up 7.05% from the previous day of trading, before settling in for the closing price of $6.95. RXRX’s price has ranged from $5.60 to $15.74 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 132.77% over the past five years. Meanwhile, its annual earnings per share averaged 2.45%. With a float of $322.67 million, this company’s outstanding shares have now reached $388.78 million.
In terms of profitability, gross margin is 3.01%, operating margin of -620.35%, and the pretax margin is -583.75%.
Recursion Pharmaceuticals Inc (RXRX) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Recursion Pharmaceuticals Inc is 17.01%, while institutional ownership is 58.14%. The most recent insider transaction that took place on Dec 11 ’24, was worth 112,182. Before that another transaction happened on Dec 10 ’24, when Company’s Officer proposed sale 15,000 for $7.75, making the entire transaction worth $116,324.
Recursion Pharmaceuticals Inc (RXRX) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.48 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 2.45% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 12.00% during the next five years compared to -43.41% drop over the previous five years of trading.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Trading Performance Indicators
Here are Recursion Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 4.35. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 44.38.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.53, a number that is poised to hit -0.41 in the next quarter and is forecasted to reach -1.66 in one year’s time.
Technical Analysis of Recursion Pharmaceuticals Inc (RXRX)
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) saw its 5-day average volume 14.47 million, a positive change from its year-to-date volume of 6.55 million. As of the previous 9 days, the stock’s Stochastic %D was 18.84%. Additionally, its Average True Range was 0.69.
During the past 100 days, Recursion Pharmaceuticals Inc’s (RXRX) raw stochastic average was set at 46.58%, which indicates a significant increase from 43.28% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 127.40% in the past 14 days, which was higher than the 82.27% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.75, while its 200-day Moving Average is $7.89. Nevertheless, the first resistance level for the watch stands at $7.91 in the near term. At $8.37, the stock is likely to face the second major resistance level. The third major resistance level sits at $8.90. If the price goes on to break the first support level at $6.92, it is likely to go to the next support level at $6.39. The third support level lies at $5.93 if the price breaches the second support level.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Key Stats
With a market capitalization of 2.89 billion, the company has a total of 286,641K Shares Outstanding. Currently, annual sales are 44,580 K while annual income is -328,070 K. The company’s previous quarter sales were 26,080 K while its latest quarter income was -95,840 K.
